The stock of Adamas Pharmaceuticals Incorporated (NASDAQ:ADMS) registered an increase of 11.27% in short interest. ADMS’s total short interest was 3.35M shares in September as published by FINRA. Its up 11.27% from 3.01 million shares, reported previously. With 248,400 shares average volume, it will take short sellers 14 days to cover their ADMS’s short positions. The short interest to Adamas Pharmaceuticals Incorporated’s float is 22.72%. About 100,047 shares traded hands. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has risen 10.43% since February 8, 2016 and is uptrending. It has underperformed by 6.05% the S&P500.
Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The company has a market cap of $354.52 million. The Firm is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems . It currently has negative earnings. The Company’s segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.
Out of 7 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 6 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 86% are positive. Adamas Pharmaceuticals has been the topic of 11 analyst reports since September 22, 2015 according to StockzIntelligence Inc. Mizuho maintained the stock on September 8 with “Buy” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.